Management of local and delayed cutaneous hypersensitivity reactions to anti-CGRP antibodies: implications for continuing treatment
- 2 June 2025
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (10) , 5431-5435
Abstract
Background Delayed local skin reactions—appearing 24 to 48 h after subcutaneous injection—such as erythema, induration, pruritus, and pain, have been reported in patients receiving anti-Calcitonin Gene-Related Peptide monoclonal antibodies (anti-CGRP mAbs). Although typically mild to moderate in severity, these reactions can occasionally be intense and may lead to treatment discontinuation due to concerns from either the clinician or the patient. Measures and intervention We developed a structured tolerance protocol consisting of four steps: administration of an oral antihistamine and topical corticosteroid as pre-injection medication, prioritization of the abdominal area for subcutaneous monoclonal antibody administration, use of oral non-steroidal antinflammatory drugs (NSAID), cold compress post-injection, and continued topical and oral treatment as needed. Outcomes This protocol was applied to three patients who had previously experienced delayed skin reactions to erenumab, galcanezumab, or fremanezumab. With the use of the protocol, all three were able to continue treatment, with symptoms either markedly reduced or fully resolved. Conclusion This protocol offers a practical and effective approach to managing local skin reactions, promoting the continued use of anti-CGRP mAbs for migraine. Its simplicity facilitates implementation even in home-based care settings.Keywords
This publication has 9 references indexed in Scilit:
- Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paperAllergy, 2023
- Injection Site Reaction to Various Insulins as Type III Allergy With Urticarial Vasculitis in a Patient With Type I Diabetes MellitusThe American Journal of Dermatopathology, 2022
- Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting SystemAdvances in Therapy, 2022
- First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine PreventionPain and Therapy, 2022
- Treatment of migraine with monoclonal antibodiesExpert Opinion on Biological Therapy, 2022
- First confirmed case of nonimmediate hypersensitivity to fremanezumab during chronic migraine treatmentContact Dermatitis, 2021
- Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort StudyHeadache: The Journal of Head and Face Pain, 2020
- CGRP, Amylin, Immunology, and Headache MedicineHeadache: The Journal of Head and Face Pain, 2018
- Heparin Allergy: Delayed-Type Non–IgE-Mediated Allergic Hypersensitivity to Subcutaneous Heparin InjectionImmunology and Allergy Clinics of North America, 2009